TY - JOUR

T1 - Managing high blood sugar (hyperglycemia) during pasireotide treatment

T2 - A plain language summary of the B2219 study

AU - Samson, Susan L.

AU - Feldt-Rasmussen, Ulla

AU - Zhang, Shao Ling

AU - Yu, Yerong

AU - Witek, Przemysław

AU - Kalra, Pramila

AU - Bolanowski, Marek

N1 - Publisher Copyright: © 2024 Susan L. Samson.

PY - 2024

Y1 - 2024

N2 - What is this summary about?: Pasireotide is a medication used to treat people with acromegaly or Cushing's disease, both of which are hormonal disorders caused by a non-cancerous tumor (adenoma) in the pituitary gland. Because of the way pasireotide works to treat these conditions, sometimes blood sugar levels can increase during treatment, causing a side effect known as hyperglycemia. This is a summary about a study called B2219 (ClinicalTrials.gov ID: NCT02060383), which was designed specifically to look at which additional medication(s) work(s) best to reduce blood sugar levels (antihyperglycemic medication) for people who require treatment for hyperglycemia while receiving pasireotide. What were the results?: Researchers found that 4 in every 10 people who took part in the; study did not develop hyperglycemia and therefore did not require antihyperglycemic medication. For those who did, metformin was a good treatment option, followed by incretin-based therapy (sitagliptin and/or liraglutide) if hyperglycemia continued. What do the results of the study mean?: This study shows that if hyperglycemia occurs during pasireotide treatment, it is manageable in most people. As such, people with acromegaly or Cushing's disease can experience long-term treatment benefits with pasireotide. Clinical Trial Registration:NCT02060383 (ClinicalTrials.gov) (B2219 study); 2012-002916-16 (B2219 study).

AB - What is this summary about?: Pasireotide is a medication used to treat people with acromegaly or Cushing's disease, both of which are hormonal disorders caused by a non-cancerous tumor (adenoma) in the pituitary gland. Because of the way pasireotide works to treat these conditions, sometimes blood sugar levels can increase during treatment, causing a side effect known as hyperglycemia. This is a summary about a study called B2219 (ClinicalTrials.gov ID: NCT02060383), which was designed specifically to look at which additional medication(s) work(s) best to reduce blood sugar levels (antihyperglycemic medication) for people who require treatment for hyperglycemia while receiving pasireotide. What were the results?: Researchers found that 4 in every 10 people who took part in the; study did not develop hyperglycemia and therefore did not require antihyperglycemic medication. For those who did, metformin was a good treatment option, followed by incretin-based therapy (sitagliptin and/or liraglutide) if hyperglycemia continued. What do the results of the study mean?: This study shows that if hyperglycemia occurs during pasireotide treatment, it is manageable in most people. As such, people with acromegaly or Cushing's disease can experience long-term treatment benefits with pasireotide. Clinical Trial Registration:NCT02060383 (ClinicalTrials.gov) (B2219 study); 2012-002916-16 (B2219 study).

KW - acromegaly

KW - Cushing's disease

KW - diabetes

KW - hyperglycaemia

KW - lay summary

KW - pasireotide

KW - plain language summary

U2 - 10.2217/frd-2023-0025

DO - 10.2217/frd-2023-0025

M3 - Journal article

AN - SCOPUS:85195147520

VL - 4

JO - Future Rare Diseases

JF - Future Rare Diseases

SN - 2399-5270

IS - 1

M1 - FRD62

ER -